MedTrace Logo

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

NCT04727996 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-04-19

No results posted yet for this study

Summary

This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.

Conditions

  • Advanced Biliary Tract Cancer

Interventions

DRUG

Sitravatinib

120 mg will be administered orally once daily

DRUG

Tislelizumab

200 mg will be administered intravenously (IV) once every 3 weeks

Sponsors & Collaborators

  • BeiGene

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Do-Youn Oh, M.D., PhD. · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2023-07-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04727996 on ClinicalTrials.gov